Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)

At present, the use of the common chemotherapy regimen CHOP/R-CHOP for diffuse large B-cell lymphoma (DLBCL) has some shortcomings, especially for relapsed and refractory DLBCL. CD47 is now considered as a prominent target in cancer therapies, and CD47 blockade mainly inhibits the CD47-SIRPα axis to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenqi, Fan, Yanfeng, Li, Meng, Yang, Linqi, Zhang, Zhenya, Liu, Lihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463246/
https://www.ncbi.nlm.nih.gov/pubmed/34567285
http://dx.doi.org/10.1155/2021/4894022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463246/
https://www.ncbi.nlm.nih.gov/pubmed/34567285
http://dx.doi.org/10.1155/2021/4894022

Ejemplares similares